Janssen Pharmaceuticals has filed a supplemental new drug application with Japanese regulators to approve Darzalex, or daratumumab, in combination with the standard of care -- which consists of Velcade, or bortezomib; melphalan; and prednisone -- to treat recently diagnosed multiple myeloma patients who are ineligible for a stem cell transplant. The same indication has already been approved for Darzalex in the US and EU.
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.